Cytotoxic Activity of Methoxy-4’amino Chalcone Derivatives Against Leukemia Cell Lines

Arina Novilla, Mustofa Mustofa, Indwiani Astuti, Jumina Jumina, Hery Suwito

Abstract


Background: Chemotherapy is a common treatment for leukemia as well as in other cancer treatment. The lack of tumor selectivity and development of multi-drug resistance by chemotherapy caused the development of new strategy in cancer treatment become a pressing need. This study was performed to evaluate the anticancer activity and selectivity of seven derivatives of chalcones against K562 and HL-60 leukemia cell lines. 

Materials and Methods: The cytotoxicity of chalcone’s seven derivatives (compound 1-7) was tested by using MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxyme-thoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) method. The percentage of cell mortality data was calculated then the IC50 was analyzed using probit analysis (SPSS 17). The selectivity index (SI) then calculated from IC50 ratio of normal lymphocyte cells and cancerous cells line (HL-60 and K562).

Results: The IC50 of almost all seven tested compounds were lower in HL-60 cell lines than K562 cell lines, except for Compound 7. The number and position of methoxy groups in chalcone derivatives influenced the anticancer and cancer selectivity of chalcone derivatives.

Conclusion: The results revealed that the number and position of methoxy groups in chalcone derivatives influenced the anticancer and cancer selectivity of chalcone derivatives.

Keywords: anticancer, chalcone derivatives, methoxy-4’-amino chalcone, leukemia, cytotoxic, selectivity


Full Text:

PDF

References


Campana D, Pui CH. Childhood leukemia. In: Niederhuber JE, Armitage JO, Dorshow JH, Kastan MB, Tepper JE, editors. Abeloff’s Clinical Oncology. 4th ed. Philadelphia: Elsevier; 2008. p.2139-69, CrossRef.

Modak H, Kulkarni S, Kadakol G, Hiremath S, Patil B, Hallikeri U, et al. Prevalence and risk of leukemia in the multi-ethnic population of North Kartanataka. Asian Pacific J Cancer Prev. 2011; 12: 671-75, Link.

Stewart BW, Wild C. World Cancer Report 2014. Lyon: International Agency for Research on Cancer; 2014, Link.

Ge H, Kong X, Shi L, Hou L, Liu Z, Li P. Gamma-linolenic acid induces apoptosis and lipid peroxidation in human chronic myelogenous leukemia K562 cells. Cell Biol Int. 2009; 33(3): 402-10, CrossRef.

Liang XJ, Chen C, Zhao Y, Wang PC. Circumventing tumor resistance to chemotherapy by nanotechnology. Methods Mol Biol. 2010; 596: 467-88, CrossRef.

Nobili S, Lippi D, Witort E, Donnini M, Bausi L, Mini E, et al. Natural compounds for cancer treatment and prevention. Pharmacol Res. 2009; 59(6): 365-78, CrossRef.

Millimouno FM, Dong J, Yang L, Li J, Li X. Targeting apoptosis pathways in cancer and perspectives with natural compounds from mother nature. Cancer Prev Res. 2014; 7(11): 1081-107, CrossRef.

Saydam G, Aydin H, Sahin F, Kucukoglu O, Erciyas E, Terzioglu E, et al. Cytotoxic and inhibitory effects of 4,4'-dihydroxy chalcone (RVC-588) on proliferation of human leukemic HL-60 cells. Leukemia Res. 2003; 27(1): 57-64, CrossRef.

Karthikeyan C, Narayana S, Narayana M, Sakthivel R, Uma V, Elangovan M, et al. Advances in chalcones with anticancer activities. Recent Pat. Anticancer Drug Discov. 2015; 10(1): 97-115, CrossRef.

Orlikova B, Tasdemir D, Golais F, Dicato M, Diederich M. Dietary chalcones with chemopreventive and chemotherapeutic potential. Genes. Nutr. 2011; 6(2): 125-47, CrossRef.

Srinivasan B, Johnson T, Lad R, Xing C. Structure-activity relationship studies of chalcone leading to 3-hydroxy-4,3',4'5'-tetramethoxychalcone and its analogues as potent nuclear factor kappa beta inhibitors and their anticancer activities. J Med Chem. 2009; 52(22): 7228-35, CrossRef.

Ducki S. Antimitotic chalcones and related compounds as inhibitors tubulin assembly. Anticancer Agents Med Chem. 2009; 9(3): 336-47, CrossRef.

Mandge S, Singh H, Gupta D, Moorthy H. Synthesis and characterization of some chalcone derivates. Trends Appl Sci Res. 2007; 2(1): 52-6, CrossRef.

Suwito H, Mustofa J, Kristanti A, Puspaningsih N. Chalcones: sythesis, structure diversity and pharmacological aspects. J Chem Pharm Res. 2014; 6(5): 1076-88, Link.

Suwito H, Jumina J, Mustofa M, Ni'matuzahroh N, Puspaningsih N. Anticancer and antimicrobial activity of methoxy amino chalcone derivates. Der Pharma Chemica. 2015; 7(3): 89-94, Link.

Yoon WJ, Ham YM, Kim SS, Yoo BS, Moon JY. Suppression of pro-inflammatory cytokines, iNOS and COX-2 expression by brown algae Sargassum micracanthum in RAW 264.7 macrophages. Eur Asia J BioSci. 2009; 3: 130-43, CrossRef.

Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. Am. J. Respir. Crit. Care Med. 1995; 151(4): 1075-82, CrossRef.

Widowati W, Mosef T, Risdian C, Yellianty Y. Anticancer and free radical scavenging potency of Catharanthus roseus, Dendrophthoe petandra, Piper betle, and Curcuma mangga extract in breast cancer cell lines. Oxid Antioxid Med Sci. 2013; 2(2): 137-42, CrossRef.

Badisa RB, Darling-Reed SF, Joseph P, Cooperwood JS, Latinwo LM, Goodman CB. Selective cytotoxic activities of two novel synthetic drugs on human breast carcinoma MCF-7 cells. Anticancer Res. 2009; 29(8): 2993-3006, Link.

Chari R. Targeted cancer therapy: confering specificity to cytotoxic drugs. Acc Chem Res. 2008; 41(1): 98-107, CrossRef.

Orlikova B, Tasdemir D, Golais F, Dicato M, Diederich M. Dietary chalcones with chemopreventive and chemotherapeutic potential. Genes Nutr. 2011; 6(2): 125-47, CrossRef.

Jandial D, Blair C, Zhang S, Krill L, Zhang Y, Zi X. Molecular targeted approaches to cancer therapy and prevention using chalcones. Curr Cancer Drug Targets. 2014; 14(2): 181-200, CrossRef.

Dimmock J, Jha A, Zello G, Allen T, Santos C, Balzarini J, et al. Cytotoxic 4'aminochalcones and related compounds. Pharmazie. 2003; 58: 227-32, Link.

Vitorovic-Todorovic M, Eric-Nikolic A, Kolundzija B, Hamel E, Ristic S, Juranic I, et al. (E)-4-aryl-4-oxo-2-butaneoic acid amides, chalcone-aroylacrylic acid chimeras: design, antiprolifetarive activity and inhibition of tubulin polymerization. Eur J Med Chem. 2013; 62: 40-50, CrossRef.

Maioral M, Gaspar P, Souza G, Mascarello A, Chiaradia L, Licino M, et al. Apoptotic events induced by sythetic naphthylchalcones in human acute leukemia cell lines. Biochimie. 2013; 95(4): 866-74, CrossRef.

Brett A, Garry R, Larry W, Burns C. Sensitivity of K562 and HL60 cells to edelfosine, an ether lipid drug, correlates with production of reactive oxygen species. Cancer Res. 1998; 58: 2809-16, Link.

Das M, Manna K. Chalcone scaffold in anticancer armamentarium: a molecular insight. J Toxicol. 2016; 2016: 7651047, CrossRef.

Li Q, Li C, Lu X, Zhang H, Zhu H. Design, synthesis and biological evaluation of novel (E)-alpha-benzylsulfonylchalcone derivatives as potential BRAF inhibitors. Eur J Med Chem. 2012; 22(2): 288-95, CrossRef.

Kong Y, Wang K, Edler M, Hamel E, Mooberry S, Paige M, et al. A boronic acid chalcone analog of combretastatin A-4 as a potent anti-proliferation agent. Bloorg Med Chem. 2010; 18(2): 971-77, CrossRef.

Ye C, Qian F, Wei D, Lu Y, Liu J. Induction of apoptosis in K562 human leukemia cells by 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone. Leukemia Res. 2005; 29: 887-92, CrossRef.

Achanta G, Modzelewska A, Feng L, Khan S, Huang P. A boronic chalcone derivative exhibits potent anti cancer activity through inhibition ofthe proteasome. Mol. Pharm. 2006; 70(1): 426-33, CrossRef.

Romagnoli R, Baraldi P, Carrion M, Cara C, Cruz-Lopez O, Preti D, et al. Design synthesis and biological evaluation of tiophene analogues of chalcones. Bioorg Med Chem. 2008; 16(1): 5367-76CrossRef.

Echeverria C, Santibanez J, Donoso-Tauda O, Escobar C, Ramirez-Tagle R. Structural antitumoral activity relationships of synthetic chalcones. Intl J Mol Sci. 2009; 10(1): 221-31, CrossRef.

Szliszka E, Czuba Z, Mazur B, Sedek L, Paradysz A, Krol W. Chalcones enhances TRAIL-induces apoptosis in prostate cancer cells. Int J Mol Sci. 2010; 11(1): 1-13, CrossRef.

Ilango K, Valentina P, Saluja G. Synthesis and in-vitro anticancer activity of some substitute chalcone derivates. Res J Pharm Biol. Chem. Sci. 2010; 1(2): 354-59, Link.

Gutierrez R, Muniz-Ramirez A, Sauceda J. Review: the potential of chalcones as a source of drugs. Afr J Pharm Pharmacol. 2015; 9(8): 237-57, CrossRef.




DOI: https://doi.org/10.21705/mcbs.v3i1.44

Copyright (c) 2019 Arina Novilla, Mustofa Mustofa, Indwiani Astuti, Jumina Jumina, Hery Suwito

Indexed by:

                     

                    

                    


Cell and BioPharmaceutical Institute